Anavex Life Sciences Corp (AVXL)

[Doc328]

Did you not notice that Missling has not most recently mentioned the ADAS-Cog result in terms other than an Odds Ratio? In his last two presentations he has only asserted the primary endpoints met without any reference to a means test. He appears to me to have backed away from that analysis, not even mentioning it in relation to the secondary CDR-SB endpoint. You would think he wouldn't have gone silent on those outcomes if he had continuing faith in using that means of analysis.

I've seen several studies where there are 2 acceptable paths for analysis and, based on the phase 2, primary and secondar endpoints are flipped in phase 3. When Anavex posts the clinicaltrials.gov listing for the phase 3 we should be able to find out whether they are going for CDR-SB change as a single primary endpoint or ADAS-Cog and ADCS-ADL change as a coprimary endpoint. Probably not going to be public before then. I am hoping with Dr. Kin's input and info gleaned from the end of phase 2 study meeting with the FDA they will design a sound P3 properly powered for approval.